Drug intelligence / Profile preview

INC102

Development stage: Preclinical
Lead developer: Liminatus Pharma
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

INC102 is an early-stage, armored chimeric antigen receptor T-cell (CAR-T) therapy candidate developed by InnocsAI. It is designed to target solid tumors expressing mesothelin and CD276 (B7-H3). As a follow-on construct to IBC101, INC102 incorporates a dominant-negative TGF-β receptor (dnTGFβR) strategy. This armoring is intended to shield the CAR-T cells from the immunosuppressive effects of TGF-β within the tumor microenvironment, thereby enhancing T-cell persistence and anti-tumor activity. The therapy is being positioned for biomarker-selected solid tumor indications.

Targets

TGFBR (TGF-beta receptor)B7-H3Mesothelin

Beyond the preview

Go deeper on INC102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INC102.

Explore the full profile